ARDS - Aridis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Aridis Pharmaceuticals, Inc.

5941 Optical Court
San Jose, CA 95138
United States
408-385-1742
http://www.aridispharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric J. PatzerExec. Chairman275kN/A1949
Dr. Vu L. TruongFounder, CEO, Chief Scientific Officer & Director607.5kN/A1964
Dr. Wolfgang Dummer M.D., Ph.D.Chief Medical Officer355kN/A1966
Mr. Fred KurlandChief Financial OfficerN/AN/A1951
Mr. Jeffrey J. Fessler J.D.Acting Gen. CounselN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.

Corporate Governance

Aridis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.